Jason H. Karp, CEO and CIO at Tourbillon Capital Partners (Photo credit: PR). Jason Karp’s Tourbillon Capital Partners recently covered its big short position on Mannkind Corp., the embattled biotechnology firm that specializes in therapeutic products for diabetes.According to